Premarket Decliner
IMVT Immunovant37.29+0.11+0.3%
Premarket:32.99-4.30 (-11.5%)
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Globe NewswireWed, 23-Sep 7:00 AM
IMVT Immunovant33.55+0.67 (+2.0%)
IMVT Immunovant33.34-2.22 (-6.2%)
IMVT 34.23+7.94 (+30.2%)Immunovant
IMVT Immunovant34.49+8.20 (+31.2%)
IMVT Immunovant29.10-0.15 (-0.5%)